Preclinical evaluation of GSK2245035, a potent and selective toll-like receptor 7 (TLR7) agonist Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
QGE031 high affinity anti-IgE: Tolerability, safety, pharmacokinetics and pharmacodynamics in atopic subjects Source: Annual Congress 2013 –Treatment of asthma Year: 2013
The allergy to insulin about a case treated by montelukast Source: International Congress 2014 – Clinical allergy Year: 2014
QAW039, a slowly dissociating CRTh2 antagonist with potential for improved clinical efficacy Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
The clinical and genetic factors for predicting the response to inhaled corticosteroids Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014
LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist Source: International Congress 2016 – Asthma management Year: 2016
Low level laser in monotherapy or in combination with leukotriene receptor antagonists in the treatment of allergic lung inflammation Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects Year: 2015
Optimal technique for measuring the IgE blocked by omalizumab Source: International Congress 2014 – Intervening in allergic asthma Year: 2014
ALX-0962, an anti-IgE Nanobody® with a dual mode of action Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016
LATE-BREAKING ABSTRACT: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen-induced early asthmatic response Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014
Immune modulation of the T-cell response in asthma through Wnt10b Source: International Congress 2014 – Exploring molecular mechanisms of allergy and asthma in animal models Year: 2014
Human T-lymphocytes are affected by notch ligands in vitro Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma Year: 2014
Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Intranasal GSK2245035 induces prolonged reductions in nasal responsiveness to allergen Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
Hypersensitivity pneumonitis: Clinical spectrum and outcome Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
Allergy symptoms in personnel from a museum complex Source: International Congress 2014 – Clinical allergy Year: 2014